MGTA News and Press, Magenta Therapeutics Inc. From 06/05/20

-- Single dose of CD45-ADC shown to remove disease-causing cells and halt disease in models of multiple sclerosis, systemic sclerosis and inflammatory arthritis -- -- MGTA-145 Phase 1 clinical data for stem cell mobilization provide a strong rationale for studying in patients with auto...

– MGTA-145 was shown to be a rapid, reliable, efficient and G-CSF-free method to obtain high numbers of functional HSCs in a Phase 1 trial; the cells could be gene modified and engraft in animals. MGTA-145 could be used to improve collection and gene therapy outcomes – &#x...

The following slide deck was published by Magenta Therapeutics, Inc. in conjunction with this Read more ...

Avrobio Collaborates with Magenta Therapeutics for Advancing Novel ADC Avrobio Inc. ( AVRO ) announced its latest collaboration with Magenta Therapeutics ( MGTA ) for advancing the latter's lead drug candidate MGTA-117. The tie-up will provide synergies for both the companies as Avrobio pr...

Magenta Therapeutics (NASDAQ: MGTA ): Q1 GAAP EPS of -$0.51 beats by $0.12 . More news on: Magenta Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

– MGTA-117 ADC clinical candidate for immune and blood system reset has demonstrated broad therapeutic index; on track for initial clinical data in 2021 – – Announced research and clinical collaboration with AVROBIO to evaluate potential utility of MGTA-117 antibod...

AVROBIO (NASDAQ: AVRO ) inks an agreement with Magenta Therapeutics (NASDAQ: MGTA ) to evaluate the potential utility of using the latter's antibody-drug conjugate MGTA-117 for conditioning patients before they receive one of the former's investigational lentiviral gene therapies. More n...

Collaboration focuses on advancing innovation with antibody-drug conjugate (ADC)-based conditioning for lentiviral gene therapies Under the collaboration, Magenta and AVROBIO will jointly evaluate MGTA-117 in conjunction with one or more of AVROBIO’s investigational gene therapi...

Collaboration focuses on advancing innovation with antibody-drug conjugate (ADC)-based conditioning for lentiviral gene therapies Under the collaboration, AVROBIO and Magenta will jointly evaluate MGTA-117 in conjunction with one or more of AVROBIO’s investigational gene therapi...

Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced it will host a conference call on Thursday, May 7, 2020 at 8:00am ET to discuss recent business updates. The ...